Bioactive vegetable proteins and peptides in lipid-lowering; nutraceutical potential

被引:10
|
作者
Ruiz Ruiz, Jorge Carlos [1 ]
Betancur Ancona, David Abram [2 ]
Segura Campos, Maira Rubi [2 ]
机构
[1] Inst Tecnol Merida, Dept Ingn Quim Bioquim, Merida, Yucatan, Mexico
[2] Univ Autonoma Yucatan, Fac Ingn Quim, Merida 97203, Yucatan, Mexico
关键词
Dyslipemias; Hypiolipidemic effect; Proteins; Peptides; DENSITY-LIPOPROTEIN RECEPTORS; ENZYME INHIBITORY PEPTIDE; SOY PROTEIN; SOYBEAN PROTEIN; CHRONIC DISEASES; CHOLESTEROL; IDENTIFICATION; LIVER; PURIFICATION; HOMEOSTASIS;
D O I
10.3305/nh.2014.29.4.7208
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
As the last century saw a decline in the burden of nutritional deficiency and infectious disease, the global burden of chronic disease, cardiovascular disease (CVD) in particular, is increasing. CVD is the leading cause of death in the developed countries. Significant research efforts on the prevention and treatment of this disease have identified elevated plasma cholesterol as a primary risk factor for CVD. Although CVD progresses with hypercholesterolemia, it seems possibility to delay and prevent its development through improvement of diet. Recent findings demonstrate that protein concentrates, protein hydrolysates, and peptides derived from vegetables may promote a significant decrease in blood cholesterol concentration. This reduction in cholesterol and lipid levels by protein, protein hydrolysates, and peptides can be the result of dietary changes, reduced cholesterol biosynthesis, changes in bile acid synthesis, and reduced absorption of lipid cholesterol and bile acid. Combination drug/diet therapies may reduce the number of drug prescriptions, the progressive rise in "optimal" drug dosage and costs associated with pharmaceutical management of disease. These bioactive vegetable proteins, hydrolysates and peptides may be used in formulation of functional foods, nutraceuticals, and natural drugs because of their health benefit effects suggesting their use as an alternative in treatment of various dyslipidemias, and a potential agent for reducing cardiovascular diseases risk factors.
引用
收藏
页码:776 / 784
页数:9
相关论文
共 50 条
  • [31] Pharmacogenetics of lipid-lowering drugs
    Kivisto, K. T.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2007, 37 : 47 - 47
  • [32] Carcinogenicity of lipid-lowering drugs
    Laws, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (19): : 1480 - 1480
  • [33] MECHANISMS OF LIPID-LOWERING AGENTS
    SIRTORI, CR
    MANZONI, C
    LOVATI, MR
    CARDIOLOGY, 1991, 78 (03) : 226 - 235
  • [34] The Future of Lipid-Lowering Therapy
    van Zwol, Willemien
    Rimbert, Antoine
    Kuivenhoven, Jan Albert
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (07)
  • [35] LIPID-LOWERING DRUGS AND VIOLENCE
    HORROBIN, DF
    BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 : 882 - 883
  • [36] Lipid-lowering efficacy of rosuvastatin
    Adams, Stephen P.
    Sekhon, Sarpreet S.
    Wright, James M.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (11):
  • [37] Lipid-Lowering Agents and Hepatotoxicity
    Demyen, Michael
    Alkhalloufi, Kawtar
    Pyrsopoulos, Nikolaos T.
    CLINICS IN LIVER DISEASE, 2013, 17 (04) : 699 - +
  • [38] Lipid-lowering therapies in development
    Wierzbicki, A. S.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 465 - 465
  • [39] PRESCRIBING LIPID-LOWERING AGENTS
    WHEATLEY, G
    BRITISH JOURNAL OF GENERAL PRACTICE, 1995, 45 (395): : 329 - 329
  • [40] Pharmacogenomics of lipid-lowering therapies
    Hu, Miao
    Tomlinson, Brian
    PHARMACOGENOMICS, 2013, 14 (08) : 981 - 995